Last reviewed 2026-05-25 · How we verify

SPEEDA and TRCS SPEEDA

Queen Saovabha Memorial Institute · FDA-approved active Biologic Under review

SPEEDA and TRCS SPEEDA is a Biologic drug developed by Queen Saovabha Memorial Institute. It is currently FDA-approved for Snake envenomation (specific species unknown). Also known as: SPEEDA, TRCS SPEEDA.

SPEEDA is a snake venom-derived antivenom or immunobiological therapeutic developed to treat envenomation or related conditions.

SPEEDA and TRCS SPEEDA are interventions being studied in a clinical trial for the treatment of rabies. The study, NCT01137045, is being conducted by the Queen Saovabha Memorial Institute to assess the immunogenicity and safety of these interventions.

At a glance

Generic name	SPEEDA and TRCS SPEEDA
Also known as	SPEEDA, TRCS SPEEDA
Sponsor	Queen Saovabha Memorial Institute
Modality	Biologic
Therapeutic area	Toxicology/Antivenom
Phase	FDA-approved

Mechanism of action

SPEEDA and TRCS SPEEDA appear to be products from the Queen Saovabha Memorial Institute, a leading Thai institution known for snake venom research and antivenom production. The exact mechanism is not clearly documented in standard pharmaceutical databases, but products from this institute typically involve neutralizing antibodies or immunoglobulins against specific venom components.

Approved indications

Snake envenomation (specific species unknown)

Common side effects

No common side effects on file.

Key clinical trials

Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SPEEDA and TRCS SPEEDA CI brief — competitive landscape report
SPEEDA and TRCS SPEEDA updates RSS · CI watch RSS
Queen Saovabha Memorial Institute portfolio CI

Frequently asked questions about SPEEDA and TRCS SPEEDA

What is SPEEDA and TRCS SPEEDA?

SPEEDA and TRCS SPEEDA is a Biologic drug developed by Queen Saovabha Memorial Institute, indicated for Snake envenomation (specific species unknown).

How does SPEEDA and TRCS SPEEDA work?

SPEEDA is a snake venom-derived antivenom or immunobiological therapeutic developed to treat envenomation or related conditions.

What is SPEEDA and TRCS SPEEDA used for?

SPEEDA and TRCS SPEEDA is indicated for Snake envenomation (specific species unknown).

Who makes SPEEDA and TRCS SPEEDA?

SPEEDA and TRCS SPEEDA is developed and marketed by Queen Saovabha Memorial Institute (see full Queen Saovabha Memorial Institute pipeline at /company/queen-saovabha-memorial-institute).

Is SPEEDA and TRCS SPEEDA also known as anything else?

SPEEDA and TRCS SPEEDA is also known as SPEEDA, TRCS SPEEDA.

What development phase is SPEEDA and TRCS SPEEDA in?

SPEEDA and TRCS SPEEDA is FDA-approved (marketed).

Manufacturer: Queen Saovabha Memorial Institute — full pipeline
Therapeutic area: All drugs in Toxicology/Antivenom
Indication: Drugs for Snake envenomation (specific species unknown)
Also known as: SPEEDA, TRCS SPEEDA

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing